Skip to main content

WHO Regional Director for Europe thanks Russia for developing Sputnik V COVID-19 vaccine

By Unknown

The Sputnik V COVID-19 vaccine, the world’s first officially registered vaccine against coronavirus, is currently undergoing post-registration trials

The Sputnik V COVID-19 vaccine is undergoing clinical trials for the coronavirus pandemic

The vaccine was registered by the Ministry of Health of Russia and became the world's first registered vaccine against SARS-CoV-2 based on the human adenoviral vectors platform

Moscow says it has received requests or 'expressions of interests' from various countries for 1.2 billion doses of the vaccine

Moscow: Hans Kluge, the Regional Director for Europe at the World Health Organization (WHO), said that the UN health agency greatly appreciates the efforts Russia has made to develop a vaccine against SARS-CoV-2, the novel coronavirus that causes COVID-19 disease, Sputnik News reported. The Sputnik V, the world’s first officially registered vaccine against COVID-19, developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology is currently undergoing post-registration trials involving about 42,000 volunteers. Meanwhile, reports from state media claimed on Thursday that the first batch of the Sputnik V vaccine has entered 'civil circulation' in Russia.

“The WHO greatly appreciates the efforts that the Russian Federation has made to develop a vaccine against COVID-19, namely Sputnik V. Once again I want to thank Russia for its excellent efforts to create a safe and effective vaccine”, Hans Kluge was quoted as saying after a meeting with Russian Minister of Health Mikhail Murashko.

According to the report, Kluge said he is confident that the ongoing post-registration trials of the Sputnik V vaccine will be successful and thanked all the volunteers who agreed to take part in clinical testing of the COVID-19 vaccine.

“Now Russia has started the third phase of vaccine testing, when the safety and effectiveness of the vaccine will be tested on a very large group of people. I am sure these results will be positive. [...] Since I have been working in Russia for many years, I know that Russia has a very rich history in the development of vaccines and their production, as well as immunisation”, he added.

On August 11, Russia registered the Sputnik V vaccine, becoming the first in the world to approve a vaccine for coronavirus amid safety concerns. Results of the phase1/2 clinical trials of the Sputnik V vaccine published in the journal The Lancet showed no serious adverse effects and a stable immune response in 100 per cent participants.

Earlier this week, it was reported that Indian firm Dr. Reddy's Laboratories Ltd could start the late-stage trials of the Sputnik V vaccine in the next week in India. The trials, which will enroll 1,000-2,000 participants, are part of a deal between Dr Reddy’s and the Russian Direct Investment Fund (RDIF). As per the deal, RDIF shall supply 100 million doses of the vaccine to Dr Reddy’s, upon regulatory approval in India.

Russia said it has signed preliminary agreements with more than 10 countries and received requests or 'expressions of interests' from various countries for 1.2 billion doses of its COVID-19 vaccine.

Worldwide, the novel coronavirus has so far claimed at least 978,448 lives and infected at least 31,975,020 people since the outbreak emerged in China last December, according to a tally from official sources compiled by AFP.


Comments

Post a Comment

Popular posts from this blog

Iran, Russia Discussing Joint Production Of COVID-19 Vaccine

By Unknown
Iran and Russia's sovereign wealth fund RDIF are discussing the joint production of a vaccine against COVID-19, Russian news agencies cited the Iranian ambassador to Moscow as saying on Friday. "We are holding talks, I spoke with the head of RDIF Kirill Dmitriev, our officials have held several rounds of consultations and we announced that we will co-operate," Ambassador to Moscow Kazem Jalali was cited as saying. Thus far, Russia has struck a manufacturing partnership deal with India, which is due to produce 300 million doses of the 'Sputnik-V' vaccine domestically. It is also discussing such partnerships with several other countries, including Brazil.
Post a Comment
Read more

Increased risks of drop out for women and girls : CoronaVirus Updates

By Unknown
The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...
Post a Comment
Read more

Russia's Covid-19 vaccine Sputnik V available to public now: State media

By Unknown
First batches of Russia's Covid vaccine Sputnik V have entered "civil circulation" in capital Moscow, state media reported on Thursday. While details on the process were not immediately available, Russia has repeatedly stressed on producing the vaccine at the earliest, a belief met with international scepticism. Earlier this month, the Russian health ministry had said that batches of the Covid-19 vaccine were being produced for public distribution and would be supplied to different regions soon. "The first batch of the vaccine for preventing the novel coronavirus infection, Gam-COVID-Vac (Sputnik V) developed by the Gamaleya Research Institute of Epidemiology and Microbiology of the Russian Health Ministry passed the required quality tests in the laboratories of Roszdravnadzor (the Federal Service for Surveillance in Healthcare) and was produced for civilian circulation. In the near future the supplies of the first batches of the vaccine to the regions are expected...
Post a Comment
Read more